{"analyses":[{"ciLowerLimit":"3.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.84","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0021","paramType":"Difference in Overall Response Rates","paramValue":"10.12","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9"},{"groupId":"OG001","value":"56.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"449"},{"groupId":"OG001","value":"450"}],"units":"Participants"}],"description":"An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"NUMBER","populationDescription":"The ORR-evaluable population is defined as patients in the ITT population with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 34 months","title":"Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in All Randomized Participants","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}